TABLE 2.

Clinical trials on the active ingredients of Tripterygium wilfordii Hook F.

Name	Condition or disease	ClinicalTrials.gov number	Sponsor	Interventions	Primary outcomes	Phase
Tripterygium Wilfordii Hook F	IgA Nephropathy	NCT02187900	Second Xiangya Hospital of Central South University	TwHF/Mycophenolate mofetil (MMF)	1.Number of patients reaching remission	Phase 3
					2.Renal survival
	Rheumatoid Arthritis	NCT04136262	Guang’anmen Hospital of China Academy of Chinese Medical Sciences	Tripterygium wilfordii Hook F (TwHF)/Methotrexate	1.Percentage of ACR20	Phase 3
					2. Percentage of ACR50
					3. Percentage of ACR70
					4. RAMRIS score
	Human Immunodeficiency Virus	NCT01666990	Beijing 302 Hospital	TwHF/Placebo treatment	1.The total CD4 T cell counts compared with CD4 T cell counts at baseline 2.The CD38 expression on CD8 T cells	Phase 2
	Arthritis, Rheumatoid	NCT01613079	Peking Union Medical College Hospital	Tripterygium wilfordii Hook F/Methotrexate	1. The proportion of patients achieving ACR50	Phase 3
					2. Radiology outcome
					3. DAS28
					4. ACR20/70
	Nephritis, Lupus	NCT01646736	Peking Union Medical College Hospital	Tripterygium wilfordii Hook F/Cyclophosphamide/GC	1. The proportion of patients achieving Complete Response (CR) and Partial Response (PR)	Phase 3
					2. Renal Function
					3. Serum Albumin Level
	Rheumatoid Arthritis	NCT03337815	Guang’anmen Hospital of China Academy of Chinese Medical Sciences	MTX and TwHF placebo/TwHF and MTX placebo	1.The change in Disease Activity Score (DAS28)	Phase 3
					2. The proportion of patients achieving ACR20/50/70
	HIV	NCT02002286	LI Taisheng, Peking Union Medical College	Tripterygium Wilfordii Hook F extrac	1. Changes of T cell subsets and immune activation markers	Not Applicable
					2. Viral load
					3. Number of participants with adverse events as a measure of safety and tolerability
Topical tripterygium gel	Arthritis, Rheumatoid	NCT02818361	Guang’anmen Hospital of China Academy of Chinese Medical Sciences	Topical tripterygium gel/Placebo gel	1.Twenty percent improvement in the American College of Rheumatology criteria	Not Applicable
					2.Twenty percent improvement in the American College of Rheumatology criteria
	Active Rheumatoid Arthritis	NCT01961505	Guang’anmen Hospital of China Academy of Chinese Medical Sciences	Topical compound Tripterygium/Placebo	1.ACR20 criteria	Not Applicable
					2. ACR50 criteria
					3. 28-joint count Disease Activity Score
Tripterygium glycosides	Inflammatory Bowel Diseases, Crohn’s Disease	NCT02044952	Zhu Weiming, Jinling Hospital, China	Tripterygium glycosides/Mesalazine	1.Therapeutic effect measured by Crohn’s Disease Activity Index (CDAI)	Phase 3
					2. The Side effects of Tripterygium wilfordii
	Early Ankylosing Spondylitis	NCT00889694	Sun Yat-sen University	Tripterygium/Sulfasalazine/placebo	1. ASAS20	Phase 3
					2. BASDAI20/50/70
	Lupus Nephritis	NCT00881309	Nanjing University School of Medicine	Tripterygium	1.Complete remission rate	Not Applicable
					2.Renal relapse
					3. Partial remission
	Diabetic Nephropathy	NCT00518362	Nanjing University School of Medicine	Tripterygium	1.To access the efficacy of TW compared to ARB in treatment of heavy proteinuria of diabetic nephropathy	Not Applicable